Neoplasms
Conditions
Brief summary
This study is planned to determine the safety and tolerability of rogaratinib in Chinese patients with fibroblast growth factor receptor (FGFR)-positive refractory, locally advanced, or metastatic solid tumors and to characterize the pharmacokinetics of rogaratinib in Chinese patients.
Interventions
Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
Sponsors
Bayer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients ≥18 years of age on the date of signing the Main Informed Consent Form. * Subjects with histologically or cytologically confirmed, refractory, locally advanced, or metastatic solid tumors who are not candidates for any standard therapy, excluding primary brain or spinal tumors. * High FGFR1, 2, 3 or 4 mRNA expression levels based on archival or fresh tumor biopsy specimen analysis (RNAscope score of 3 or 4) * At least one measurable lesion outside the central nervous system according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) A lesion in a previously irradiated area is eligible and to be considered measurable disease as long as there is objective evidence of progression of the lesion prior to study enrollment. Patients with resected primary tumors who have documented metastases are eligible. * Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 * Life expectancy of at least 3 months * Adequate bone marrow, liver and renal function as assessed by laboratory requirements conducted within 7 days before the first dose of rogaratinib: * Hemoglobin (Hb) ≥9.0 g/dL (without transfusion or erythropoietin within 4 weeks before screening) * Absolute neutrophil count (ANC) ≥1,500/mm3 * Platelet count ≥100,000/mm3 * Total bilirubin ≤1.5 times the upper limit of normal (ULN). Documented or diagnosed constitutional jaundice such as Gilbert syndrome is allowed if total bilirubin is mildly elevated (\<6 mg/dL). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN (≤5 times ULN for patients with liver involvement of their cancer) * Alkaline phosphatase ≤2.5 times ULN (≤5 times ULN for patients with liver involvement of their cancer) * Amylase and lipase ≤2.5 times ULN * Serum creatinine ≤1.5 x ULN and glomerular filtration rate (GFR) ≥30 mL/min/1.73 m2, according to the Modified Diet in Renal Disease (MDRD) abbreviated formula
Exclusion criteria
\- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study. The following previous or concurrent cancer types might be acceptable: cervical carcinoma in situ, treated basal cell carcinoma, locally confined prostate cancer, or any cancer curatively treated \>3 years before the start of rogaratinib. \- Symptomatic brain or meningeal or spinal metastases. Asymptomatic brain or meningeal or spinal metastases are acceptable if all of the following criteria are met: * Definitive therapy completed \>6 months before the start of rogaratinib * No evidence of the growth of brain or meningeal or spinal metastases on an imaging test performed within 4 weeks before the start of rogaratinib * Clinically and radiologically stable with respect to the tumor at the time of study entry * Moderate or severe liver cirrhosis (Child-Pugh class B or C) * History or current evidence of altered endocrine regulation of calcium phosphate homeostasis (e.g. parathyroidectomy, parathyroid disorder, tumor lysis, tumoral calcinosis) * Any previous drug / procedure-related toxicity (patients with persistent alopecia, anemia, and / or hypothyroidism can be included) not recovered to National Cancer Institute's Common Terminology Criteria for Adverse Event, version 4.03 (CTCAE v4.03) Grade 0 or 1 or not recovered to baseline preceding the prior treatment * Current diagnosis of any retinal disorders including retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion. * Previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase inhibitors including rogaratinib or FGFR-specific antibodies)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC(0-12)md: AUC(0-12) after multiple dosing | Cycle 1 Day 15 (each cycle is 21 days) | Multiple dose |
| AUC(0-12): AUC from time zero to 12 hours p.a. after first-dose administration | Cycle 1 Day 1 (each cycle is 21 days) | Single dose |
| Cmax,md: Cmax after multiple dosing | Cycle 1 Day 15 (each cycle is 21 days) | Multiple dose |
| Frequency of Treatment-Emergent Adverse Events(TEAEs) | 30 days after last dose of rogaratinib | — |
| Severity of Treatment-Emergent Adverse Events(TEAEs) | 30 days after last dose of rogaratinib | — |
| Cmax: Maximum drug concentration in plasma after dose administration | Cycle 1 Day 1 (each cycle is 21 days) | Single dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | Within 7-14 days after the last dose of rogaratinib | Response rate is defined as the proportion of patients who have a best overall response rating of complete response (CR) and partial response (PR) that is achieved during treatment. |
| Phosphate levels | Within 7-14 days after the last dose of rogaratinib | — |
Countries
China
Outcome results
None listed